Clinical trials: Cancer Related Pain (Breakthrough Pain)
Breakthrough Cancer Pain
Treatment of Breakthrough Cancer Pain According to European Guidelines
Pain is a frequent symptom in cancer patients with a negative impact on the quality of life (QoL).Breakthrough cancer pain (BTcP) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific…
- Trial name
- BEG (NCT04468490)
- Where
- Poland
- Volunteers
- 131 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01693328)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Archimedes Development Ltd
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01698645)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Archimedes Development Ltd
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough…
- Trial name
- NCT04713189
- Testing
- Inhaled fentanyl aerosol
- Volunteers
- 96 people
- Sponsor
- Lee's Pharmaceutical Limited
Breakthrough Pain
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Patients treated in Palliative Care Units are potentially fragile patients, especially in our case, which are cancer patients. The management of these patients is usually done from experience, because these patients rarely meet…
- Trial name
- CAVIDIOPAL (NCT02840500)
- Testing
- No intervention
- Where
- 10 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Angelini Farmacéutica
Cancer Pain
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00459277
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Archimedes Development Ltd
Pain
An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients
The purpose of this study is to evaluate the analgesic effectiveness and safety of 37.5mg Tramadol hydrochloride/325mg Acetaminophen in the treatment of breakthrough pain in cancer patients.
- Trial name
- NCT00576173
- Testing
- tramadol hydrochloride; acetaminophen
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.
- Trial name
- NCT05531422
- Testing
- Inhaled fentanyl aerosol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Lee's Pharmaceutical Limited
Cancer, Pain
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
- Trial name
- NCT00538863
- Testing
- Fentanyl sublingual spray
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 319 people
- Sponsor
- INSYS Therapeutics Inc
Cancer, Breakthrough Cancer Pain
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain episode, which takes place within stable background pain control.
- Trial name
- REBORN (NCT03564548)
- Testing
- PPP001, Morphine sulfate or Hydromorphone or Oxycodone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tetra Bio-Pharma
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc